HONG KONG – Aiming to address a perceived disparity in the quality of manufacturing of drugs for the China market, the CFDA is ramping up its focus on offshore drug manufacturers. The regulator last year stepped up the number of overseas good manufacturing practice (GMP) inspections it carried out, while domestically, it put more of the onus on companies to police themselves.
HONG KONG – Catching up with international markets, China is unbinding its drug manufacturing licensing regime from the marketing authorization in a move aimed at revolutionizing the country's drug development space.
HONG KONG – In a move to improve its drug manufacturing, research and development capacity as well as to strengthen its international presence, Shanghai Fosun Pharmaceutical (Group) Co. Ltd. made an offer to acquire a 96 percent stake in Indian drugmaker Gland Pharma Ltd.
HONG KONG – In a move to improve its drug manufacturing, research and development capacity as well as to strengthen its international presence, Shanghai Fosun Pharmaceutical (Group) Co. Ltd. made an offer to acquire a 96 percent stake in Indian drugmaker Gland Pharma Ltd.
